MAKENZIE SCHEMBARI: Open Payments
NPI 1124742424 · NEW ALBANY, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 25 payments from 10 companies in 2025. Trend: 2023 $2,067 · 2024 $1,683 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $244 |
| AstraZeneca Pharmaceuticals LP | 3 | $159 |
| Janssen Biotech, Inc. | 1 | $112 |
| PFIZER INC. | 3 | $55 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $53 |
| Novo Nordisk Inc | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Boston Scientific Corporation | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $14 |
Products named: VRAYLAR, LYNPARZA, RYBREVANT, ELAHERE, PREVNAR 20, Kerendia, CAPLYTA, Ozempic.
Industry payments across IN — which companies pay providers there.
